Acorda Therapeutics
 | |
| Public | |
| Traded as | NASDAQ: ACOR FWB: CDG |
| Industry |
Health care Biotechnology |
| Founded | 1995[1] |
| Founder | Ron Cohen |
| Headquarters | Ardsley, New York, United States |
Key people |
Ron Cohen Andrew R. Blight |
| Products |
Zanaflex Ampyra Qutenza |
| Revenue |
 US$292.2 Million (FY 2011)[2] |
|
US$35.1 Million (FY 2011)[2] | |
|
US$30.6 Million (FY 2011)[2] | |
| Total assets |
US$379.5 Million (FY 2011)[2] |
| Total equity |
US$205.2 Million (FY 2011)[2] |
Number of employees | 328 (February, 2012) [2] |
| Website | Acorda.com |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
History
In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.[4]
In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.[5]
Corporate governance
As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were:[6] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.
Products
Products on the market
Products under development
- CVT-301
- Plumiaz (discontinued May 20th, 2016)
References
- ↑ Acorda FAQ
- 1 2 3 4 5 6 "Acorda Therapeutics 2011 Annual Report - Form 10-K - February 28, 2012." (PDF). secdatabase.com. Retrieved May 16, 2012.
- ↑ Acorda 2008 10-K Annual report
- ↑ "Acorda Buys Civitas and Its Phase III PD Candidate for $525M - GEN News Highlights - GEN".
- ↑ "Accorda Acquires Biotie Therapies for $363 Million - GEN News Highlights - GEN".
- ↑ "Leadership ← Acorda".